These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 7319116)

  • 1. Continuous subcutaneous insulin infusion in the treatment of juvenile-onset diabetes.
    Buysschaert M; Lejeune M; Lambert AE
    Diabete Metab; 1981 Sep; 7(3):189-93. PubMed ID: 7319116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
    Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
    Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.
    Bruttomesso D; Crazzolara D; Maran A; Costa S; Dal Pos M; Girelli A; Lepore G; Aragona M; Iori E; Valentini U; Del Prato S; Tiengo A; Buhr A; Trevisan R; Baritussio A
    Diabet Med; 2008 Mar; 25(3):326-32. PubMed ID: 18307459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Continuous subcutaneous insulin infusion (CSII) in treating young diabetic patients].
    Buczkowska EO; Dworzecki T; Wiedermann G; Malanowicz B; Szot D
    Przegl Lek; 2005; 62(1):49-53. PubMed ID: 16053222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Continuous subcutaneous insulin infusion brings about normal blood sugar in type I diabetes mellitus despite relaxing of diet instructions].
    Sonnenberg GE; Chantelau E; Altenähr H; Berger M; Berchtold P
    Schweiz Med Wochenschr; 1982 Jan; 112(3):83-5. PubMed ID: 7036337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ambulatory treatment of diabetes in children by continuous subcutaneous infusion of insulin using a portable pump].
    Bougnères PF; Landier F; Lemmel C; Golse B; Chaussain JL
    Arch Fr Pediatr; 1984 Jan; 41(1):27-33. PubMed ID: 6721650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues.
    Torres I; Ortego J; Valencia I; García-Palacios MV; Aguilar-Diosdado M
    Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):378-85. PubMed ID: 19629931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucose profiles in a type 1 diabetic patient successively treated with CSII using regular insulin, lispro and an implantable insulin pump.
    Catargi B; Breilh D; Roger P; Tabarin A
    Diabetes Metab; 2000 May; 26(3):210-4. PubMed ID: 10880895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substitution of basal delivery of insulin by proinsulin in type I diabetic patients under CSII.
    Kerner W; Wallmüller G; Beischer W; Pfeiffer EF
    Horm Metab Res Suppl; 1988; 18():74-7. PubMed ID: 3056816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin kinetics in type I diabetic patients treated by continuous intraperitoneal insulin infusion: influence of anti-insulin antibodies.
    Lassmann-Vague V; Belicar P; Alessis C; Raccah D; Vialettes B; Vague P
    Diabet Med; 1996 Dec; 13(12):1051-5. PubMed ID: 8973887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Benefits of subcutaneous continuous insulin infusion in type 1 diabetic patients with high glycemic variability].
    Prieto-Tenreiro A; Villar-Taibo R; Pazos-Couselo M; González-Rodríguez M; Casanueva F; García-López JM
    Endocrinol Nutr; 2012 Apr; 59(4):246-53. PubMed ID: 22440045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term benefits of continuous subcutaneous insulin infusion in children with Type 1 diabetes: a 4-year follow-up.
    Sulli N; Shashaj B
    Diabet Med; 2006 Aug; 23(8):900-6. PubMed ID: 16911629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Assessment of metabolic control and safety of continuous subcutaneous insulin infusion in prepubertal children with type 1 diabetes mellitus].
    Minkina-Pedras M; Jarosz-Chobot P; Małecka-Tendera E; Deja G
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2005; 11(3):171-6. PubMed ID: 16232370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of various methods of intensive insulin therapy in hospital condition assessed by hypoglycaemic episodes detected with the use of continuous glucose monitoring system.
    Mozdzan M; Ruxer J; Loba J; Siejka A; Markuszewski L
    Adv Med Sci; 2006; 51():133-6. PubMed ID: 17357293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin pump treatment: effect on glucose homeostasis, metabolites, hormones, insulin antibodies and quality of life.
    Beck-Nielsen H; Richelsen B; Schwartz Sørensen N; Hother Nielsen O
    Diabetes Res; 1985 Jan; 2(1):37-43. PubMed ID: 3888495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of premeal subcutaneous insulin infusion and injection in type I diabetic patients under continuous basal subcutaneous insulin delivery.
    Navascués I; Kerner W; Pfeiffer EF
    Life Support Syst; 1985; 3(3):263-7. PubMed ID: 3900596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetics treated with continuous subcutaneous insulin infusion pumps.
    Foley-Nolan D; Foley-Nolan A; Temperley D; Devlin J
    Ir Med J; 1989 Dec; 82(4):159-60. PubMed ID: 2516015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized pilot study in Type 1 diabetes complicated by severe hypoglycaemia, comparing rigorous hypoglycaemia avoidance with insulin analogue therapy, CSII or education alone.
    Thomas RM; Aldibbiat A; Griffin W; Cox MA; Leech NJ; Shaw JA
    Diabet Med; 2007 Jul; 24(7):778-83. PubMed ID: 17535290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-mediated glucose disposal in type 1 (insulin-dependent) diabetic subjects treated by continuous subcutaneous or intraperitoneal insulin fusion.
    Beylot M; Khalfallah Y; Laville M; Sautot G; Dechaud H; Serusclat P; Berthezene F; Riou JP; Mornex R
    Diabete Metab; 1987; 13(4):450-6. PubMed ID: 3315766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Present role of continuous subcutaneous insulin infusion (CSII) by insulin pump in the treatment of diabetes mellitus].
    Pfützner A; Berger S; Spinas G
    Schweiz Med Wochenschr; 2000 Dec; 130(48):1854-61. PubMed ID: 11132530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.